Last reviewed · How we verify
NV1020
At a glance
| Generic name | NV1020 |
|---|---|
| Sponsor | MediGene |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver (PHASE1, PHASE2)
- Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NV1020 CI brief — competitive landscape report
- NV1020 updates RSS · CI watch RSS
- MediGene portfolio CI